Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

12.58 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Astria Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗

March 28, 2023

Via Benzinga

Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

March 22, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Earnings Outlook For Astria Therapeutics ↗

March 21, 2023

Via Benzinga

Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd

March 08, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference

March 06, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 02, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting

February 24, 2023

From Astria Therapeutics

Via Business Wire

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting

February 21, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE

February 08, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2023

From Astria Therapeutics, Inc.

Via Business Wire

MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday ↗

December 22, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

$10 Million Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

December 22, 2022

Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades.

Via Benzinga

Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 19, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday ↗

December 19, 2022

Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on...

Via Benzinga

Dow Dips Over 800 Points; S&P 500 Down 2.8% ↗

December 15, 2022

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 800 points.

Via Benzinga

Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session ↗

December 15, 2022

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.

Via Benzinga

RCI Hospitality, AbCellera Biologics And Some Other Big Stocks Moving Higher On Thursday ↗

December 15, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 600 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Astria Therapeutics' Potential Hereditary Angioedema Candidate Shows Encouraging Action In Healthy Participants ↗

December 15, 2022

Via Benzinga

Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

December 15, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects

December 15, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 02, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

November 10, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

November 09, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting

November 07, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 02, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development

September 16, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present at Upcoming Investment Conferences

September 06, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

August 09, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 04, 2022

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.